In my previous articles, I have discussed my expectations related to the impact of changing tax reforms on Pfizer (NYSE:PFE). I have also given a detailed account of the major cancer drugs in Pfizer's portfolio, considered to be the key growth drivers for the company in 2017.
In addition to a robust drug portfolio, I strongly believe that Pfizer also has one seriously undervalued research pipeline. Based on this premise, I have been bullish for this stock since October 2016. To further clarify my point, I will be explaining some of the recently approved drugs as well as promising research programs from the company's pipeline in greater detail.
